Hansoh Pharmaceutical (03692.HK): NMPA Accepts New Drug Application for Orlotide Injection

NewTimeSpace · 2026/06/04 08:17 · By Boyuan Chen

NewTimeSpace News: Hansoh Pharmaceutical announced on June 4 that the New Drug Application (NDA) of its self-developed innovative drug Orlotide Injection has been accepted by the National Medical Products Administration (NMPA), indicated for long-term weight management in obese or overweight adults.

NewTimeSpace News: On June 4, 2026, Hansoh Pharmaceutical (03692.HK) issued a voluntary announcement, disclosing that on June 3, 2026, the marketing authorization application for its in-house innovative product Orlotide Injection was accepted by the National Medical Products Administration (NMPA). The indication covers long-term weight management for adult patients with obesity or overweight.

Orlotide is a once-weekly dual agonist targeting GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

Hansoh Pharmaceutical 03692.HK